Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX2001 Monotherapy in Advanced Solid Tumors
NCT06239194Phase 2Recruiting
- Sponsor
- ModeX Therapeutics
- Start
- Jun 2024
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, T-cell Engagers, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of MDX2001 in solid tumor, sponsored by ModeX Therapeutics. Started Jun 2024; status: recruiting.
02
Drugs
MDX2001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06239194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239194.